National Jewish Medical and Research Center
National Jewish Medical and Research Center is known worldwide for treatment of patients with respiratory, immune and allergic disorders, and for groundbreaking medical research. Founded in 1899 as a nonsectarian, nonprofit hospital for tuberculosis (TB) patients, National Jewish remains the only facility in the world dedicated exclusively to these disorders.
Four years in a row, U.S. News & World Report's "America's Best Hospitals" ranked National Jewish number one in the nation for excellence in treating respiratory diseases, and first in reputation among pulmonary specialists.
American Health magazine termed National Jewish one of the finest U.S. hospitals in allergy, immunology and pulmonology for both adult and pediatric patients. The Institute for Science and Medicine rated National Jewish among the top 10 independent biomedical research institutions-of any kind-in the world, and the only one that also provides patient care. National Jewish was ranked as one of the three most influential research institutions for immunology and as the number one private immunology research institution in the world.
For more information, or to contact National Jewish Medical and Research Center, see their website at: www.njc.org
» Recent News
Severe Childhood Asthma: What Are We Missing?
08 Jul 03 | Researchers at National Jewish Medical and Research Center highlight significant shortcomings in the prevailing model of severe asthma in an article published in the July issue of Chest.
Philippa Marrack to Be Honored for Lifetime Achievement in Immunology
04 May 03 | National Jewish researcher Philippa Marrack, Ph.D., will receive the American Association of Immunologists Lifetime Achievement Award Tuesday, May 5. Dr. Marrack's research has focused on T cells, a pivotal part of the immune system.
Binding Studies Suggest Drug Development Strategy for Lupus
30 Apr 03 | Researchers have figured out how Tall-1, a protein implicated in the disease lupus, binds to its main receptor, Baff-R. The findings suggest that a small fragment of the Baff-R receptor could be developed as a treatment for lupus.
Medication Protects Patients with Peanut Allergies
10 Mar 03 | A new medication could help most people with peanut allergies avoid life-threatening allergic reactions, according to a report in the March 14 issue of the New England Journal of Medicine.
Bacterial Infections Alter Allergic Response
25 Feb 03 | Researchers at National Jewish Medical and Research Center have gathered strong experimental support for the hygiene hypothesis, a proposed explanation for the worldwide rise in asthma and allergies.
National Jewish Offers Free Medical Screening for People Who Helped at the World Trade Center Site
03 Feb 03 | Many people from Colorado and surrounding states who helped with rescue, recovery, and clean-up efforts at the World Trade Center are at risk for respiratory and other health problems.
National Jewish to Pilot Disease Management for Department of Defense
21 Jan 03 | A pilot study of disease management for pediatric asthma is being launched at three military bases in Oklahoma and Texas by the Department of Defense, in cooperation with National Jewish Medical and Research Center.
National Jewish to Study Chemical Hazards in 'Meth Labs'
14 Jan 03 | Researchers at National Jewish Medical and Research Center are accompanying law enforcement and health officers on seizures of clandestine methamphetamine laboratories, to better understand the hazards posed by toxic chemicals in these illegal labs.
National Jewish to Manage Asthma Patients for Colorado Medicaid
13 Jan 03 | In an effort to control burgeoning Medicaid costs, the state of Colorado has contracted with National Jewish Medical and Research Center to provide disease management services for its Medicaid patients with asthma.
National Jewish Provides Full COPD Disease-Management Program to Providence Health Plan
10 Jan 03 | National Jewish Medical and Research Center has agreed to provide a complete disease-management program for chronic obstructive pulmonary disease (COPD) to Providence Health Plans, which serves patients in Oregon and Washington.